BioSpace News Archive

With the advent of new technology, the potential that next generation sequencing application holds in genetic counseling, disease management and treatment, and risk assessment is remarkable.

MicroPort Scientific Corporation announced that MicroPort Cardiac Rhythm Management Limited, which is MicroPort®'s subsidiary focused on developing and commercializing implantable pacemaker and defibrillator devices and related technologies to manage cardiac rhythm disorders, has entered into definitive agreements in connection with its Series C financing with total investment proceeds of US$150 million.

Deciphera Pharmaceuticals, Inc. announced that it will report its second quarter 2021 financial results on Tuesday, August 3, 2021.

Cardiovascular Systems, Inc., a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced that management plans to attend three investor conferences in August.

Verastem Oncology announced that an abstract detailing updated results from the ongoing Phase 1/2 FRAME study investigating VS-6766, the Company’s RAF/MEK inhibitor, in combination with defactinib, its FAK inhibitor, in patients with low grade serous ovarian cancer has been selected for a mini oral presentation at the upcoming European Society of Medical Oncology Congress 2021, taking place virtually September 16-21, 2021.

XyloCor Therapeutics, a clinical-stage biopharmaceutical company developing novel gene therapies for cardiovascular disease, announced the completion of the Phase 1 dose-escalation component of its Phase 1/2 clinical trial of XC001, its lead investigational gene therapy candidate for patients with refractory angina who have no further treatment options.

Oragenics, Inc. announced it has entered into a licensing agreement with the National Research Council of Canada that will enable Oragenics to pursue the rapid development of next-generation vaccines against the SARS-CoV-2 virus and its variants.

Harmony Biosciences Holdings, Inc., a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, announced that it will issue a press release on the Company’s second quarter 2021 financial results on Tuesday, August 10, 2021 at 8:00 a.m. ET.

BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, today announced a non-exclusive, co-funded clinical collaboration with Bristol Myers Squibb to evaluate the combination of BBP-398, a potentially best-in-class SHP2 inhibitor, with OPDIVO® (nivolumab)

iXensor Co., Ltd. (6734.TWO) launches the next generation of integrated COVID-19 screening solution, the PixoHealth Pass Admin App and Web Portal.